Immuron Limited (IMRN)
Automate Your Wheel Strategy on IMRN
With Tiblio's Option Bot, you can configure your own wheel strategy including IMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMRN
- Rev/Share 1.866
- Book/Share 1.3711
- PB 2.4295
- Debt/Equity 0.0146
- CurrentRatio 5.0747
- ROIC -0.9856
- MktCap 18964649.3828
- FreeCF/Share -1.5715
- PFCF -2.0602
- PE -2.4823
- Debt/Assets 0.0116
- DivYield 0
- ROE -0.8549
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target
Published: October 17, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-month price target of $4.00, representing over 80% upside from the Company's recent closing price of $2.20. The initiation report highlights Immuron's proprietary polyclonal antibody platform, strong revenue growth from its over-the-counter product Travelan®, and an expanding clinical pipeline addressing major global infectious diseases.
Read More
Immuron partners with InvestorHub
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors.
Read More
Immuron - FY25 global sales exceed projection, up 49% on prior year
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement …
Read More
About Immuron Limited (IMRN)
- IPO Date 2017-06-09
- Website https://www.immuron.com.au
- Industry Biotechnology
- CEO Steven George Lydeamore CPA,
- Employees 7